Nutrient supplements and methods for treating autism and for preventing the onset of autism

Patent 7232575 Issued on June 19, 2007. Estimated Expiration Date:

September 25, 2026. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

Nutritional supplement for the elderly
Patent #: 5556644
Issued on: 09/17/1996
Inventor: Chandra

Nutritional supplement for the prevention and treatment of excessive intestinal permeability
Patent #: 5976579
Issued on: 11/02/1999
Inventor: McLean

Allelic polygene diagnosis of reward deficiency syndrome and treatment
Patent #: 6132724
Issued on: 10/17/2000
Inventor: Blum

Nutritional supplement for the prevention and treatment of excessive intestinal permeability
Patent #: 6143332
Issued on: 11/07/2000
Inventor: McLean

Nutritional supplement
Patent #: 6245360
Issued on: 06/12/2001
Inventor: Markowitz

Nutritional system for nervous system disorders Patent #: 6399114
Issued on: 06/04/2002
Inventor: Foreman

Inventors

Assignee

The Health Research Institute

Application

No. 11526383 filed on 09/25/2006

US Classes:

424/439, Food or edible as carrier for pharmaceutical426/72, PRODUCT WITH ADDED VITAMIN OR DERIVATIVE THEREOF FOR FORTIFICATION426/73, Vitamin is A or D424/630, Copper424/692, Magnesium hydroxide or oxide424/641Zinc

Examiners

Primary: Tran, S.

Attorney, Agent or Firm

Merchant & Gould

Foreign Patent References

0 891 719 EP 01/01/1999
WO 91/11117 WO 08/01/1991
WO 9111117 WO 08/01/1991
WO 98/41113 WO 09/01/1998
WO 00/67596 WO 11/01/2000
WO 01/26642 WO 04/01/2001

International Classes

A61K 47/00
A23L 1/30

Abstract

Provided by the present invention are novel and non-obvious nutrient supplements that preferably comprise minerals, vitamins, amino acids, and agents capable of delivering cysteine in vivo. The nutrient supplements desirably are capable of promoting metallothioneins, and optionally, promoting the removal of excess metals from the bloodstream. Also provided by the invention are methods of treating autism involving administration of the nutrient supplements. The methods include treatment to prevent or slow down the onset of autism once a predisposition for the development of autism has been detected, and treatment to alleviate or reverse the symptoms of autism once autism has been diagnosed. The invention further provides methods of administering the nutrient supplements in the treatment of other diseases, disorders and conditions, that would benefit from such administration, especially those that would benefit from metallothionein promotion and/or removal of excess metals from the bloodstream.

Other References

Walsh et al., “Eleveated Blood Cooper/Zinc Ratios in Assaultive Young Males,” Physiology & Behavior, vol. 62, No. 2, 1997.
Isaacson et al., “Autism: A Retrospectice Outcome Study of Nutrient Therapy,” Journal of Applied Nutrition, vol. 48, No. 4, 1996.
Kirkman Laboratories, Inc., Kirkman's HypoAllergenic NuThera® Capsules [http://www.kirkmanlabs.com/products/articles/nutherap5p.htm] 1-3 (Mar. 2002).
Kirkman Laboratories, Inc., “Super NuThera®” [http://www.kirkmanlabs.com/products/articles/supernuthera.htm] 1-19 (Mar. 11, 2002).
Kirkman Laboratories, Inc., “Super Nu-Thera with P5P” [http://www.kirkmanlabs.com/products/articles/supernutherap5p.htm] 1-3 (Mar. 11, 2002).
Maret, “The Function of Zinc Metallothionein: A Link between Cellular Zinc and Redox State”, J. Nutr. 130(No. 5, Suppl.): 1455S-1458S (May 2000).
Sullivan et al., “Metallothionein Expression Is Increased in Monocytes and Erythrocytes of Young Men during Zinc Supplementation”, J. Nutr. 128:7077-713 (1998).
Suzuki et al, “Table I. Factors that induce thionein synthesis in cultured cells in vivo”, In, Metallothionein III: Biological Roles & Medical Implications, Birkhauser Verlag, un-numbered page (1993).
Walsh et al., “Disordered Metal Metabolism in a Large Autism Population”, Abstract NR823, American Psychiatric Association Annual Meeting, New Orleans, LA (May 10, 2001).
Walsh et al. “Elevated Blood Copper/Zinc Ratios in Assaultive Young Males” Physiology & Behavior, 62(2):327-329 (1997).
Walsh et al., “Metallothionein and Autism”, Pfeiffer Treatment Center, 1804 Centre Point Drive, Naperville, Illinois, 60563 (Oct. 2001).
Walsh et al. “Metallothionein Protein Dysfunction in Autism spectrum Disorders”, Abstract for International Meeting For Autism Research, San Diego, CA (Nov. 9-10, 2002).
Autism Research Publication, “Parent Ratings of Behavioral Effects of Drugs,. Nutrients, and Diets.” ART Publ. 34, Autism Research Institute, 4182 Adarns Avenue, San Diego, CA 921 16 (Sep. 2000).
Fischer et al., “Commentary: Recent excitement regarding metallothionein”, Proc. Natl Acad. Sci. USA. 95:3333-3334 (Mar. 1998).
Isaacson et al., “Autism: A Retrospective Outcome Study of Nutrient Therapy,” Journal of Applied Nutrition, 48(4):2-6 (1996).
Jacob et al., “Control of zinc transfer between thionein, metallothionein, and zinc proteins,” Proc. Natl Acad. Sci. USA, 95:3489-3494 (Mar. 1998).
Jiang et al., “The Glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbitol dehydrogenate,” Proc. Natl Acad. Sci. USA. 95 :3483-3488 (Mar. 1998).
Karen, from the autismandenzymes Yahoo.Group, William Walsh -PfeifferJMetallathionein* [http: //www.bbbautism.dan˜william_—walsh.html] 1-9.
Kirkman Laboratories, Inc., “Kirkman's Amino-Support” 1 [http: //www .kirkmanlabs.com/products/articles/aminosupport.htm] 1-5 (Mar. 11, 2002).
Cutler, “Pyridoxine and Trace Element Therapy in Selected Clinical Cases.” Orthomolecular Psychiatry. vol. 3. No. 2, pp. 89-95 (1 974).
Isaacson et al., “A Retrospective Outcome Study of Nutrient Therapy.” Journal of Applied Nutrition, vol. 48. No. 4, pp. 11 0-1 18 (1 996).
Adams et al., “Vitamin, mineral supplements benefits people with autism”.